This study compared real-world overall survival (rwOS) among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) initiating first-line covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapy with zanubrutinib, acalabrutinib, or ibrutinib using the PurpleLab CLEAR claims database.
This retrospective cohort study used PurpleLab CLEAR claims data, which included open and closed medical and pharmacy claims across commercial, Medicare, and Medicaid coverage. Eligible adult patients with CLL/SLL (≥2 CLL/SLL diagnostic codes on ≥2 distinct dates) who initiated first-line cBTKi monotherapy with zanubrutinib, acalabrutinib, or ibrutinib between January 2020 and February 2026 were included (data cutoff: May 29, 2026). Mortality data were assessed and linked across multiple data sources. Median real-world overall survival (rwOS) and survival probabilities at 24 and 36 months were estimated using the Kaplan-Meier method. Hazard ratios and 95% CIs were estimated using crude and inverse probability of treatment weighting (IPTW)-weighted Cox proportional hazards models, with IPTW using stabilized weights derived from a multinomial propensity score model based on index year, age, sex, Charlson Comorbidity Index (CCI), geographic region, and race/ethnicity. Prespecified subgroup analyses were conducted by age, sex, and CCI.
A total of 23,168 patients met eligibility criteria, including 5,893 treated with zanubrutinib, 9,423 with acalabrutinib, and 7,852 with ibrutinib. Median age overall was 75 years (interquartile range [IQR], 69-80). Medicare was the most common payer (55.7%), followed by commercial insurance (35.0%). Most patients were male (60.5%) and Non-Hispanic White (61.5%), with a median CCI of 3. The most common baseline comorbidities were hypertension (68.6%) and diabetes (29.9%). Median follow-up was 17 months for zanubrutinib, 24 months for acalabrutinib, and 36 months for ibrutinib, consistent with regulatory approval milestones.
During follow-up, 5,200 deaths were recorded. Median rwOS was not reached in any treatment group. Zanubrutinib-treated patients had higher survival probabilities at 24 months (86.8%; 95% CI, 85.5-88.2) and 36 months (83.1%; 95% CI, 81.3-84.9) compared with acalabrutinib (83.1% [95% CI, 82.2-83.9] and 77.3% [95% CI, 76.2-78.3]) and ibrutinib (81.3% [95% CI, 80.2-82.5] and 75.0% [95% CI, 73.7-76.3]; all P<0.0001).
In both crude and IPTW-weighted analyses, zanubrutinib was associated with significantly lower all-cause mortality versus acalabrutinib (crude HR, 0.81 [95% CI, 0.74-0.88]; weighted HR, 0.75 [95% CI, 0.67-0.84]; P<0.0001) and ibrutinib (crude HR, 0.67 [95% CI, 0.61-0.72]; weighted HR, 0.68 [95% CI, 0.60-0.77]; P<0.0001).
Results were generally consistent across prespecified subgroups, except for age <65 years which was the smallest subgroup and may have been underpowered. Zanubrutinib was associated with better survival than acalabrutinib among patients aged 65-74 years (weighted HR, 0.69 [95% CI, 0.52-0.92]), aged ≥75 years (weighted HR, 0.74 [95% CI, 0.65-0.84]), with CCI ≤3 (weighted HR, 0.67 [95% CI, 0.55-0.81]), and CCI >3 (weighted HR, 0.79 [95% CI, 0.69-0.92]). Similarly, zanubrutinib was associated with better survival than ibrutinib among patients aged 65-74 years (weighted HR, 0.64 [95% CI, 0.48-0.86]), aged ≥75 years (weighted HR, 0.67 [95% CI, 0.59-0.77]), with CCI ≤3 (weighted HR, 0.58 [95% CI, 0.48-0.70]), and CCI >3 (weighted HR, 0.74 [95% CI, 0.63-0.86]).
The authors noted that the study period overlapped with the COVID-19 pandemic, which may limit generalizability of findings to other time periods.